CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 136 enrolled
Drug / intervention
Capecitabine +2 moredrug
Likely dose
Capecitabine 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01423604
NCT01423604Phase 2Completed
CompareCT.gov

A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)

Incyte Corporation·interventional·Posted Aug 26, 2011·Updated Feb 12, 2018

In Brief

A Phase 2 clinical trial evaluating Capecitabine, Ruxolitinib, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 136 participants across 39 sites.

Detailed Summary

The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 26, 2011
Enrollment StartJul 1, 2011
Primary CompletionJun 1, 2013
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.8 years ago

Interventions

Capecitabinedrug

Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)

Ruxolitinibdrug

Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)

Placebodrug

Placebo matching ruxolitinib